# US 2024/0197651 A1 · Dexmecamylamine and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197651 A1
- Document ID: US20240197651A1
- Status: Published application
- Kind: A1
- Application number: 18/572,977
- Filed: 2022-06-24
- Published: 2024-06-20
- Earliest claimed: 2021-06-24
- Assignees: Atacama Therapeutics, Inc.
- Applicants: Atacama Therapeutics, Inc.
- Inventors: Joseph A. BARON; Jonathan REIS
- Web page: https://patentgrep.com/patent/US20240197651A1

## CPC

- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61P 17/00: Drugs for dermatological disorders
- A61K 8/41: Amines
- A61P 17/08: Antiseborrheics
- A61P 17/10: Anti-acne agents
- A61P 35/00: Antineoplastic agents
- A61Q 19/008: {Preparations for oily skin}
- A61Q 19/08: Anti-ageing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The disclosure features methods of treating a subject with acne, enlarged pores, hidradenitis, seborrhea, sebaceous hyperplasia, seborrheic dermatitis, sebaceous adenoma, sebaceous carcinoma, sebaceous cyst, wrinkles, or oily skin suppurativa by administration of a dexmecamylamine substantially free of exo-R-mecamylamine, or a pharmaceutically acceptable salt thereof to the subject.

## Claims

### Claim 1

A method of treating acne, enlarged pores, hidradenitis suppurativa, seborrhea, sebaceous hyperplasia, seborrheic dermatitis, sebaceous adenoma, sebaceous carcinoma, sebaceous cyst, wrinkles, or oily skin in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of dexmecamylamine substantially free of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has acne

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has enlarged pores.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has hidradenitis suppurativa.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has seborrhea.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject has a sebaceous hyperplasia.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject has seborrheic dermatitis.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject has a sebaceous adenoma.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject has a sebaceous carcinoma.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject has a sebaceous cyst.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject has wrinkles.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject has oily skin.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the dexmecamylamine, or pharmaceutically acceptable salt thereof, is administered is administered by way of oral, inhalational, intranasal, or topical administration.

### Claim 14 (depends on 13)

The method of any one of claim 13, wherein the subject is administered 0.1 mg to 16 mg of the dexmecamylamine substantially free of exo-R-mecamylamine, or pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the subject is administered 0.1 mg to 16 mg of the dexmecamylamine substantially free of exo-R-mecamylamine, or pharmaceutically acceptable salt thereof for two weeks or more.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein dexmecamylamine hydrochloride is administered.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, wherein the subject is administered 2 mg of the dexmecamylamine substantially free of exo-R-mecamylamine, or pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 15, 16)

The method of claim 15 or 16, wherein the subject is administered 4 mg of the dexmecamylamine substantially free of exo-R-mecamylamine, or pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein, prior to treatment, the subject produces sebum in an amount of 100 μg/cm2 or greater.

### Claim 20 (depends on 19)

The method of claim 19, wherein the subject produces sebum in an amount of 125 μg/cm2, 135 μg/cm2, 150 μg/cm2, 175 μg/cm2, 200 μg/cm2 or greater.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein following the treatment with dexmecamylamine substantially free of exo-R-mecamylamine, or pharmaceutically acceptable salt thereof, the subject exhibits sebum production that is at least 20% less than the sebum production in the subject prior to the treatment with the dexmecamylamine substantially free of exo-R-mecamylamine, or pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the sebum production is facial sebum production.
